🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

195 results for “Boehringer Ingelheim” Clear

  1. Afatinib

    Boehringer Ingelheim

    Head and Neck Neoplasms

    phase 3 small molecule completed

    1 trial

  2. An open label, single arm, extension trial to examine long-term safety of Iclepertin once daily in patients with schizophrenia who have completed previous Iclepertin Phase III trials.(CONNEX-X)

    Boehringer Ingelheim

    Schizophrenia

    phase 3 other active

    1 trial

  3. Avtozma 20 mg/mL concentrate for solution for infusion., BI 764532, Carboplatin Hikma 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Etoposid Hikma 20 mg/ml Konzentrat zur Herstellung einer Infusionslösung

    Boehringer Ingelheim

    advanced or metastatic extrapulmonary neuroendocrine carcinoma

    phase 3 small molecule active

    1 trial

  4. BI 1015550, BI 1015550

    Boehringer Ingelheim

    idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF)

    phase 3 small molecule active

    1 trial

  5. BI 1015550, Placebo matching BI 1015550, BI 1015550

    Boehringer Ingelheim

    Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

    phase 3 small molecule active

    1 trial

  6. BI 1015550, Placebo matching nerandomilast (BI 1015550)

    Boehringer Ingelheim

    Systemic Autoimmune Rheumatic Diseases associated Interstitial Lung Diseases (SARD-ILD)

    phase 3 small molecule active

    1 trial

  7. BI 10773

    Boehringer Ingelheim

    Diabetes Mellitus, Type 2

    phase 3 small molecule completed

    1 trial

  8. BI 1291583

    Boehringer Ingelheim

    Bronchiectasis

    phase 3 small molecule active

    1 trial

  9. BI 201335

    Boehringer Ingelheim

    Hepatitis C

    phase 3 small molecule completed

    1 trial

  10. BI 201335

    Boehringer Ingelheim

    Hepatitis C, Chronic

    phase 3 small molecule completed

    1 trial

  11. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  12. BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, Placebo, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  13. BI 456906, BI 456906, BI 456906, BI 456906, Placebo matching products 1 to 7 (pre-filled syringe, filling volume: 0.5 mL), BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity

    phase 3 small molecule active

    1 trial

  14. BI 456906, Placebo, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906, BI 456906

    Boehringer Ingelheim

    Obesity, Diabetes mellitus type II

    phase 3 small molecule active

    1 trial

  15. BI 695501

    Boehringer Ingelheim

    Arthritis, Rheumatoid

    phase 3 small molecule completed

    2 trials

  16. BI 764198

    Boehringer Ingelheim

    Focal Segmental Glomerulosclerosis

    phase 3 small molecule active

    1 trial

  17. BI 764198, Placebo matching BI 764198

    Boehringer Ingelheim

    Focal segmental glomerulosclerosis

    phase 3 small molecule active

    1 trial

  18. BI 907828, BI 907828, BI 907828

    Boehringer Ingelheim

    dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  19. BI 907828, BI 907828, Doxorubicin-Ebewe, 2 mg/ml, koncentrat do sporządzania roztworu do infuzji, BI 907828

    Boehringer Ingelheim

    Advanced dedifferentiated liposarcoma

    phase 3 small molecule active

    1 trial

  20. Brigimadlin

    Boehringer Ingelheim

    Liposarcoma, Dedifferentiated

    phase 3 small molecule completed

    1 trial

  21. EMPAGLIFLOZIN, BI 690517, Placebo matching vicadrostat

    Boehringer Ingelheim

    Heart failure

    phase 3 small molecule active

    1 trial

  22. EMPAGLIFLOZIN, Placebo matching BI 690517, BI 690517

    Boehringer Ingelheim

    Heart failure (HF)

    phase 3 small molecule active

    1 trial

  23. Empagliflozin

    Boehringer Ingelheim

    Chronic Kidney Disease

    phase 3 small molecule active

    1 trial

  24. Empagliflozin

    Boehringer Ingelheim

    Myocardial Infarction

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources